KIM-1 (human) ELISA Kit
Catalog #ADI-900-226
96-Well Enzyme Immunoassay Kit
USE FOR RESEARCH PURPOSES ONLY

Unless otherwise specified expressly on the packaging, all products sold hereunder are intended for and may be used for research purposes only and may not be used for food, drug, cosmetic or household use or for the diagnosis or treatment of human beings. Purchase does not include any right or license to use, develop or otherwise exploit these products commercially. Any commercial use, development or exploitation of these products or development using these products without the express written authorization of Enzo Life Sciences, Inc. is strictly prohibited. Buyer assumes all risk and liability for the use and/or results obtained by the use of the products covered by this invoice whether used singularly or in combination with other products.

LIMITED WARRANTY; DISCLAIMER OF WARRANTIES

These products are offered under a limited warranty. The products are guaranteed to meet all appropriate specifications described in the package insert at the time of shipment. Enzo Life Sciences’ sole obligation is to replace the product to the extent of the purchasing price. All claims must be made to Enzo Life Sciences, Inc., within five (5) days of receipt of order. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF OTHERS, AND ALL SUCH WARRANTIES (AND ANY OTHER WARRANTIES IMPLIED BY LAW) ARE EXPRESSLY DISCLAIMED.

TRADEMARKS AND PATENTS

Several Enzo Life Sciences products and product applications are covered by US and foreign patents and patents pending.

FOR RESEARCH USE ONLY.

NOT FOR USE IN DIAGNOSTIC PROCEDURES.
# Table of Contents

- Background ...................................................................................... 2
- Principle .......................................................................................... 3
- Materials Supplied ........................................................................... 4
- Storage ............................................................................................... 5
- Other Materials Needed ..................................................................... 5
- Sample Handling ............................................................................... 6
- Reagent Preparation ......................................................................... 8
- Assay Procedure ............................................................................... 9
- Calculation of Results ...................................................................... 10
- Typical Results ................................................................................ 11
- Performance Characteristics ............................................................ 12
- References ......................................................................................... 13
- Contact Information .......................................................................... 14

Please read entire booklet before proceeding with the assay.
BACKGROUND

The human KIM-1 (kidney injury molecule-1) ELISA kit is a complete kit for the quantitative determination of KIM-1 in urine. Please read the complete kit insert before performing this assay.

Chronic kidney disease (CKD) is a major public health problem, as one in nine American adults have CKD. There have been numerous studies focused on this disease over the years but there remains a need for improved therapeutics and identifying and/or predicting patient outcomes. One protein that has been identified as playing an important role in kidney disease is Kidney Injury Molecule-1 (KIM-1). KIM-1 is a 30KDa, type 1 membrane protein with an ectodomain that contains immunoglobulin (Ig) and highly O-glycosylated mucin subdomains as well as multiple N-glycosylation sites. It is the most highly upregulated protein in the proximal tubule of the injured kidney. It exists in very low levels in normal kidneys but when upregulated during injury, it is detectable in urine in a wide variety of human diseases. KIM-1 may be a biomarker for renal injury, which would suggest it has great importance in various kidney diseases and disorders, such as chronic kidney disease (as mentioned above), as well as acute tubular necrosis and acute kidney failure.

This product is licensed from the General Hospital Corporation and is protected by US patents 6,664,385 B1, 7,041,290 B2 and 7,696,321.
**PRINCIPLE**

1. The kit uses a monoclonal antibody to KIM-1 immobilized on a microtiter plate to bind the KIM-1 in the standards or sample.

2. After a short incubation the excess sample or standard is washed out and a biotinylated monoclonal antibody to KIM-1 is added. This antibody binds to the KIM-1 captured on the plate.

3. After a short incubation the excess antibody is washed out and Streptavidin conjugated to Horseradish peroxidase is added, which binds to the biotin on the monoclonal antibody. The plate is then incubated.

4. Once the incubation is complete, excess conjugate is washed out and TMB substrate solution is added. An HRP-catalyzed reaction generates a blue color in the solution.

5. Stop solution is added to stop the substrate reaction. The resulting yellow color is read at 450 nm. The amount of signal is directly proportional to the level of KIM-1 in the sample.
MATERIALS SUPPLIED

1. KIM-1 Microtiter plate
   One plate of 96 wells, Product No. 80-2557
   A clear plate of break-apart strips coated with a monoclonal antibody specific to KIM-1

2. KIM-1 Standard, 25 ng/mL
   0.5ml, Product No. 80-2558
   One vial containing 25 ng/mL of recombinant KIM-1

3. KIM-1 Detector Antibody
   10 mL, Product No. 80-2559
   A yellow solution of biotinylated monoclonal antibody to KIM-1

4. KIM-1 Conjugate
   10 mL, Product No. 80-2560
   A blue solution of Streptavidin conjugated to Horseradish peroxidase

5. Assay Buffer 13
   60 mL, Product No. 80-1500
   Tris buffered saline containing BSA and detergents

6. TMB Substrate
   10 mL, Product No. 80-0350
   A solution of 3,3',5,5' tetramethylbenzidine (TMB) and hydrogen peroxide

7. Stop Solution 2
   10 mL, Product No. 80-0377
   A 1N solution of hydrochloric acid in water

8. Wash Buffer Concentrate
   100 mL, Product No. 80-1287
   20x Tris buffered saline containing detergent

9. KIM-1 Assay Layout Sheet
   1 each, Product No. 30-0315

10. Plate Sealer
    3 each, Product No. 30-0012
STORAGE
All kit components are stable at 4°C until the kit’s expiration date. Shipping conditions may not reflect storage conditions.

OTHER MATERIALS NEEDED
1. Deionized or distilled water
2. Precision pipets for volumes between 5 µL and 1,000 µL
3. Repeater pipet for dispensing 100 µL
4. Disposable beakers for diluting buffer concentrates
5. Graduated cylinders
6. A microplate shaker
7. Adsorbent paper for blotting
8. Microplate reader capable of reading a 450 nm
9. Software (such as AssayBlaster™ catalog number ADI-28-0002) for extrapolating sample values from optical density readings utilizing a four parameter logistic curve fit.
SAMPLE HANDLING

The KIM-1 ELISA is compatible with KIM-1 samples in urine. Samples diluted sufficiently into Assay Buffer 13 can be read directly from a standard curve. Urine samples must be diluted at least 1:4 with Assay Buffer 13 in order to remove matrix interference effects. The minimal recommended dilution may not be optimal for all urine samples for the levels of endogenous KIM-1 could vary between sample groups. Therefore it is up to each end user to optimize the dilution for their unique set of samples.

Linearity

The minimum required dilution for urine is 1:4. This was determined by serially diluting kidney disease-state urine samples into the provided assay buffer and identifying the dilution at which linearity was observed.

<table>
<thead>
<tr>
<th>Dilution</th>
<th>Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neat</td>
<td>---</td>
</tr>
<tr>
<td>1:4</td>
<td>100%</td>
</tr>
<tr>
<td>1:8</td>
<td>108%</td>
</tr>
<tr>
<td>1:16</td>
<td>95%</td>
</tr>
<tr>
<td>1:32</td>
<td>88%</td>
</tr>
</tbody>
</table>
Parallelism

To assess parallelism, human urine was serially diluted into assay buffer and run in the assay. The KIM-1 concentration in each sample was assigned using the standard curve. Assigned concentrations were plotted as a function of sample dilution. Parallelism of the curves demonstrates that the antigen binding characteristics are similar enough to allow the accurate determination of native analyte levels in diluted samples of human origin.

Spike and Recovery

After diluting each individual sample to read within the dynamic range of the assay, recombinant KIM-1 was spiked at a high concentration into neat urine, diluted 1:4 and then serially (1:2) into assay buffer. Endogenous KIM-1 was subtracted from the spiked values and the recovery in each of the spiked specimens was compared to the recovery of identical spikes in the assay buffer. The percent recovery of each concentration is indicated below for human urine.

<table>
<thead>
<tr>
<th>Sample Matrix</th>
<th>Dilution</th>
<th>Spike Concentration (pg/mL)</th>
<th>% Recovery of Spike</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human urine</td>
<td>1:4</td>
<td>400</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>200</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>127</td>
</tr>
</tbody>
</table>
REAGENT PREPARATION

1. **Wash Buffer**

   Prepare Wash buffer by diluting 50 mL of the supplied Wash Buffer concentrate with 950 mL of deionized water. Store the diluted wash buffer at room temperature. Diluted wash buffer should be used within 3 months.

2. **KIM-1 Standard**

   Allow the KIM-1 standard to warm to room temperature. Label seven 12x75 mm polypropylene tubes #1 through #7. Pipet 490 µL of Assay Buffer 13 into tube #1. Pipet 250 µL of Assay Buffer 13 into tube #2 through tube #7. Add 10 µL of 25,000 pg/mL KIM-1 standard stock to tube #1. Add 250 µL of tube #1 into tube #2 and vortex. Add 250 µL of tube #2 to tube #3 and vortex thoroughly. Continue this for tubes #4 through #7.

   ![](image)

   Diluted standards should be used within 60 minutes of preparation. Discard any unused standard dilutions.

   All other kit components should be brought to room temperature prior to use in the assay.
ASSAY PROCEDURE

Refer to the Assay Layout Sheet to determine the number of wells to be used. Remove the wells not needed for the assay and return them, with the desiccant, to the mylar bag and seal. Store unused wells at 4°C.

1. Pipet 100 µL of Assay Buffer 13 into the S0 (0 pg/mL standard) and NSB wells. Leave the Blank wells empty.
2. Pipet 100 µL of standards #1 through #7 to the bottom of the appropriate wells.
3. Pipet 100 µL of the samples into the appropriate wells.
4. Seal the plate. Incubate for 30 minutes with mixing* on a plate shaker at room temperature.
5. Empty the contents of the wells and wash by adding ~300 µL of 1X Wash Buffer to each well. Empty or aspirate the wells and repeat the wash 3 more times for a total of 4 washes. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
6. Pipet 100 µL of yellow Antibody into each well, except the NSB and blank wells. Add 100 µL Assay Buffer 13 into NSB wells and leave Blank wells empty.
7. Seal the plate and incubate for 30 minutes with mixing on a plate shaker at room temperature.
8. Empty the contents of the wells and wash by adding ~300 µL of 1X Wash Buffer to each well. Empty or aspirate the wells and repeat the wash 3 more times for a total of 4 washes. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
9. Add 100 µL of blue Conjugate to each well, except the Blank.
10. Seal the plate and incubate for 30 minutes with mixing on a plate shaker at room temperature.
11. Empty the contents of the wells and wash by adding ~300 µL of 1X Wash Buffer to each well. Empty or aspirate the wells and repeat the wash 3 more times for a total of 4 washes. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
12. Pipet 100 µL of TMB solution into each well.
13. Seal the plate. Incubate for 20 minutes with shaking on a plate shaker at room temperature.

Bring all reagents to room temperature for at least 30 minutes prior to opening.

All standards and samples should be run in duplicate.

Pipet the reagents to the sides of the wells to avoid possible contamination.

All standards and samples should be run in duplicate.

Pipet the reagents to the sides of the wells to avoid possible contamination.

All standards and samples should be run in duplicate.

Pipet the reagents to the sides of the wells to avoid possible contamination.
14. Pipet 100 µL of Stop Solution into each well.

15. After blanking the plate reader against the substrate, read optical density at 450 nm. If the plate reader is not capable of adjusting for the blank, manually subtract the mean OD of the substrate blank from all readings.

*Note:* The optimal speed for each shaker will vary and may range from 120-700 rpm. The speed must be set to ensure adequate mixing of the wells, but not so vigorously that the contents of the wells splash out and contaminate other wells.

**CALCULATION OF RESULTS**

Several options are available for the calculation of the concentration of KIM-1 in the samples. We recommend that the data be handled by an immunoassay software package utilizing a 4 parameter logistic (4PL) curve fitting program. Assay Blaster! Data analysis software (Prod. no. ADI-28-0002) is an easy-to-use and cost effective program that provides the options of point-to-point, 4PL and 5PL curve fitting options. The concentration of KIM-1 can be calculated as follows:

1. Calculate the average net OD for each standard and sample by subtracting the average NSB OD from the average OD for each standard and sample.

   \[
   \text{Average Net OD} = \text{Average OD} - \text{Average NSB OD}
   \]

2. Using data analysis software, plot the Average Net OD for each standard versus KIM-1 concentration in each standard.
TYPICAL RESULTS

The results shown below are for illustration only and should not be used to calculate results.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Mean OD</th>
<th>Net OD</th>
<th>KIM-1 (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank</td>
<td>(0.001)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSB</td>
<td>0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S0</td>
<td>0.058</td>
<td>0.054</td>
<td>0</td>
</tr>
<tr>
<td>S1</td>
<td>2.058</td>
<td>2.054</td>
<td>500</td>
</tr>
<tr>
<td>S2</td>
<td>1.075</td>
<td>1.071</td>
<td>250</td>
</tr>
<tr>
<td>S3</td>
<td>0.562</td>
<td>0.558</td>
<td>125</td>
</tr>
<tr>
<td>S4</td>
<td>0.298</td>
<td>0.294</td>
<td>62.5</td>
</tr>
<tr>
<td>S5</td>
<td>0.175</td>
<td>0.171</td>
<td>31.3</td>
</tr>
<tr>
<td>S6</td>
<td>0.113</td>
<td>0.109</td>
<td>15.625</td>
</tr>
<tr>
<td>S7</td>
<td>0.081</td>
<td>0.077</td>
<td>7.813</td>
</tr>
</tbody>
</table>

TYPICAL STANDARD CURVE

Typical standard curves are shown below. These curves must not be used to calculate KIM-1 concentrations; each user must run a standard curve for each assay.
PERFORMANCE CHARACTERISTICS

The following parameters for this kit were determined using the guidelines listed in the National Committee for Clinical Laboratory Standards (NCCLS) Evaluation Protocols6.

Specificity

The cross reactivities of related compounds were determined by diluting the cross reactant in the kit assay buffer at a concentration of ten times the high standard and then measuring in the assay.

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Cross Reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIM-3</td>
<td>≤0.02%</td>
</tr>
<tr>
<td>TIM-4</td>
<td>≤0.02%</td>
</tr>
</tbody>
</table>

Sensitivity

The sensitivity or limit of detection of the assay is 1.279 pg/mL, determined by interpolation at 2 standard deviations away from the mean signal of 10 replicates of 0 pg/mL. Data was used from 4 standard curves.

Interference

Protease inhibitors commonly used in clinical specimens were analyzed for interference in the assay and the tolerance was determined.

<table>
<thead>
<tr>
<th>Protease inhibitor</th>
<th>Assay Tolerance</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIC</td>
<td>≤2.5%</td>
</tr>
<tr>
<td>PMSF</td>
<td>≤1 mM</td>
</tr>
<tr>
<td>Aprotinin</td>
<td>≤100 ug/mL</td>
</tr>
</tbody>
</table>
**Intra-assay precision** was determined by assaying 20 replicates of three buffer controls containing KIM-1 in a single assay.

<table>
<thead>
<tr>
<th>Intra-assay precision</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>pg/mL</td>
<td>%CV</td>
</tr>
<tr>
<td>385.5</td>
<td>1.8</td>
</tr>
<tr>
<td>93.1</td>
<td>2.3</td>
</tr>
<tr>
<td>39.3</td>
<td>2.6</td>
</tr>
</tbody>
</table>

**Inter-assay precision** was determined by measuring buffer controls of varying KIM-1 concentrations in multiple assays over several days.

<table>
<thead>
<tr>
<th>Inter-assay precision</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>pg/mL</td>
<td>%CV</td>
</tr>
<tr>
<td>397.5</td>
<td>6.2</td>
</tr>
<tr>
<td>99.8</td>
<td>6.4</td>
</tr>
<tr>
<td>39.7</td>
<td>1.9</td>
</tr>
</tbody>
</table>

**REFERENCES**
